Header Logo

Connection

KAREN RABIN to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Back to Details
This is a "connection" page, showing publications KAREN RABIN has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
KAREN RABIN
Connection Strength
10.864
Precursor Cell Lymphoblastic Leukemia-Lymphoma
  1. Management of Down Syndrome-Associated Leukemias: A Review. JAMA Oncol. 2023 09 01; 9(9):1283-1290.
    View in: PubMed
    Score: 0.499
  2. Insights into the genomics of iAMP21-ALL. Blood. 2023 08 24; 142(8):682-684.
    View in: PubMed
    Score: 0.498
  3. Genetic Ancestry and Childhood Acute Lymphoblastic Leukemia Subtypes and Outcomes in the Genomic Era. JAMA Oncol. 2022 03 01; 8(3):342-343.
    View in: PubMed
    Score: 0.449
  4. Risk stratification for Down syndrome and acute lymphocytic leukaemia: one size does not fit all. Lancet Haematol. 2021 Oct; 8(10):e673-e675.
    View in: PubMed
    Score: 0.437
  5. Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrome genetic backgrounds. PLoS One. 2021; 16(1):e0244863.
    View in: PubMed
    Score: 0.415
  6. Optimizing Targeted Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA Oncol. 2020 03 01; 6(3):333-334.
    View in: PubMed
    Score: 0.391
  7. Need for new thinking: Treatment of relapsed leukemia in children with Down syndrome. Pediatr Blood Cancer. 2019 06; 66(6):e27644.
    View in: PubMed
    Score: 0.363
  8. First do no harm: infectious deaths in pediatric ALL. Blood. 2014 Aug 14; 124(7):987-9.
    View in: PubMed
    Score: 0.266
  9. Reply to "Peripheral blood lymphocyte recovery and overall survival in pediatric acute lymphoblastic leukemia". Pediatr Blood Cancer. 2014 Jan; 61(1):180.
    View in: PubMed
    Score: 0.249
  10. The adolescent and young adult with cancer: state of the art-- acute leukemias. Curr Oncol Rep. 2013 Aug; 15(4):317-24.
    View in: PubMed
    Score: 0.248
  11. Attacking remaining challenges in childhood leukemia. N Engl J Med. 2012 Apr 12; 366(15):1445-6.
    View in: PubMed
    Score: 0.226
  12. Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Apr; 58(4):633-5.
    View in: PubMed
    Score: 0.220
  13. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Sep; 59(3):468-74.
    View in: PubMed
    Score: 0.220
  14. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia. 2011 Oct; 25(10):1555-63.
    View in: PubMed
    Score: 0.214
  15. Management strategies in acute lymphoblastic leukemia. Oncology (Williston Park). 2011 Apr 15; 25(4):328-35.
    View in: PubMed
    Score: 0.211
  16. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009 Nov; 41(11):1243-6.
    View in: PubMed
    Score: 0.191
  17. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009 Mar; 144(6):930-2.
    View in: PubMed
    Score: 0.180
  18. Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res. 2009 Feb; 33(2):336-9.
    View in: PubMed
    Score: 0.176
  19. Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008 Aug; 51(2):171-7.
    View in: PubMed
    Score: 0.175
  20. Personalized care of pediatric cancer patients. Nestle Nutr Workshop Ser Pediatr Program. 2008; 62:173-85; discussion 185-8.
    View in: PubMed
    Score: 0.168
  21. An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy. Blood Adv. 2025 Nov 25; 9(22):5802-5810.
    View in: PubMed
    Score: 0.146
  22. Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
    View in: PubMed
    Score: 0.141
  23. Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
    View in: PubMed
    Score: 0.137
  24. Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025 Mar; 39(3):555-567.
    View in: PubMed
    Score: 0.136
  25. Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
    View in: PubMed
    Score: 0.135
  26. Cerebral Sinus Venous Thrombosis in Pediatric Acute Lymphoblastic Leukemia: Incidence, Clinical Characteristics, and Long-term Neurologic Outcomes. J Child Neurol. 2024 Nov; 39(13-14):494-499.
    View in: PubMed
    Score: 0.134
  27. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3491-3503.
    View in: PubMed
    Score: 0.133
  28. Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
    View in: PubMed
    Score: 0.132
  29. Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Leukemia. 2024 04; 38(4):720-728.
    View in: PubMed
    Score: 0.129
  30. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.
    View in: PubMed
    Score: 0.127
  31. Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia. Pediatr Blood Cancer. 2024 Jan; 71(1):e30726.
    View in: PubMed
    Score: 0.126
  32. Down syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica. 2023 10 01; 108(10):2570-2581.
    View in: PubMed
    Score: 0.125
  33. Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome. Blood Adv. 2023 08 08; 7(15):3928-3931.
    View in: PubMed
    Score: 0.124
  34. Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30585.
    View in: PubMed
    Score: 0.124
  35. Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. 2023 07 13; 142(2):172-184.
    View in: PubMed
    Score: 0.123
  36. Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):900-904.
    View in: PubMed
    Score: 0.120
  37. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy. 2023 03; 43(3):205-214.
    View in: PubMed
    Score: 0.120
  38. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023 Feb; 10(2):e129-e141.
    View in: PubMed
    Score: 0.120
  39. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer. 2023 04 15; 129(8):1287-1294.
    View in: PubMed
    Score: 0.120
  40. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022 11; 69(11):e29937.
    View in: PubMed
    Score: 0.117
  41. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022 09; 54(9):1376-1389.
    View in: PubMed
    Score: 0.116
  42. Epigenome-wide association study of acute lymphoblastic leukemia in children with Down syndrome. Blood Adv. 2022 07 26; 6(14):4132-4136.
    View in: PubMed
    Score: 0.116
  43. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. Lancet Haematol. 2022 Sep; 9(9):e678-e688.
    View in: PubMed
    Score: 0.115
  44. A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 05 01; 107(5):1185-1188.
    View in: PubMed
    Score: 0.114
  45. CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome. Exp Hematol. 2022 06; 110:34-38.
    View in: PubMed
    Score: 0.113
  46. Residence in a Latinx enclave and end-induction minimal residual disease positivity among children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2022 Oct; 39(7):650-657.
    View in: PubMed
    Score: 0.113
  47. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022 05 01; 128(9):1863-1870.
    View in: PubMed
    Score: 0.112
  48. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol. 2021 Oct 01; 7(10):1521-1528.
    View in: PubMed
    Score: 0.109
  49. Converging genetic and epigenetic drivers of paediatric acute lymphoblastic leukaemia identified by an information-theoretic analysis. Nat Biomed Eng. 2021 04; 5(4):360-376.
    View in: PubMed
    Score: 0.106
  50. Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. Pediatr Blood Cancer. 2021 08; 68(8):e29036.
    View in: PubMed
    Score: 0.105
  51. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28929.
    View in: PubMed
    Score: 0.104
  52. Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood. 2021 01 21; 137(3):364-373.
    View in: PubMed
    Score: 0.104
  53. Area deprivation is associated with poorer overall survival in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020 09; 67(9):e28525.
    View in: PubMed
    Score: 0.100
  54. Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. Anticancer Res. 2020 Jun; 40(6):3147-3153.
    View in: PubMed
    Score: 0.100
  55. Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatr Blood Cancer. 2021 09; 68(9):e28315.
    View in: PubMed
    Score: 0.099
  56. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020 07; 34(7):1741-1750.
    View in: PubMed
    Score: 0.098
  57. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood. 2019 10 10; 134(15):1227-1237.
    View in: PubMed
    Score: 0.095
  58. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. Blood Adv. 2019 06 11; 3(11):1647-1656.
    View in: PubMed
    Score: 0.093
  59. Maternal Residential Proximity to Major Roadways and the Risk of Childhood Acute Leukemia: A Population-Based Case-Control Study in Texas, 1995-2011. Int J Environ Res Public Health. 2019 06 07; 16(11).
    View in: PubMed
    Score: 0.093
  60. Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. PLoS One. 2018; 13(5):e0197408.
    View in: PubMed
    Score: 0.086
  61. Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility. PLoS One. 2017; 12(8):e0180488.
    View in: PubMed
    Score: 0.082
  62. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics. Cancer. 2016 Dec 01; 122(23):3697-3704.
    View in: PubMed
    Score: 0.077
  63. Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients. Am J Clin Pathol. 2015 Aug; 144(2):263-70.
    View in: PubMed
    Score: 0.071
  64. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 02; 123(1):70-7.
    View in: PubMed
    Score: 0.063
  65. Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
    View in: PubMed
    Score: 0.062
  66. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011 Aug; 25(8):1365-8.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.